Patents by Inventor Renier Myburgh

Renier Myburgh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141043
    Abstract: The present invention relates to a bispecific antibody comprising at least a first binding domain and a second binding domain, wherein said first binding domain binds to an organic fluorophore and wherein said second binding domain binds to CD3, and to a combination thereof with a labelled binding agent that binds specifically to a target antigen, wherein the labelled binding agent is labelled with an organic fluorophore.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 2, 2024
    Inventors: Dario NERI, Renier MYBURGH, Markus MANZ, Laura VOLTA
  • Publication number: 20230242643
    Abstract: Chimeric antigen receptor (CAR) bridging protein are provided comprising a CAR-binding domain linked to an antigen-binding domain, which can be used to re-direct the targeting of CAR-T cells. The bridging protein may comprie an antigen-binding domain that targets any antigen of interest, such as, for example, a tumor antigen or viral antigen. Also provided are methods of using the bridging proteins in combination with CAR-T cells to treat a disease, such as, for example, a cancer or an infectious disease.
    Type: Application
    Filed: May 27, 2021
    Publication date: August 3, 2023
    Applicants: ANTION BIOSCIENCES SA, GENEVA UNIVERSITY HOSPITALS, UNIVERSITY OF GENEVA, UNIVERSITY OF ZURICH
    Inventors: Marco ALESSANDRINI, Karl-Heinz KRAUSE, Renier MYBURGH
  • Patent number: 11649455
    Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 16, 2023
    Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICH
    Inventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
  • Patent number: 11613747
    Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: March 28, 2023
    Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICH
    Inventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
  • Publication number: 20220315653
    Abstract: The present invention relates to a bispecific binding agent comprising at least a first binding domain and a second binding domain, wherein said first binding domain binds to CD117/c-KIT and wherein said second binding domain binds to CD3.
    Type: Application
    Filed: September 4, 2020
    Publication date: October 6, 2022
    Inventors: Jonathan KIEFER, Renier MYBURGH, Markus MANZ, Dario NERI
  • Publication number: 20210095278
    Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.
    Type: Application
    Filed: April 1, 2019
    Publication date: April 1, 2021
    Applicants: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICH
    Inventors: Karl-Heinz KRAUSE, Francis ROUSSET, Patrick SALMON, Marco ALESSANDRINI, Roberto SPECK, Simon BREDL, Tafadzwa MLAMBO, Renier MYBURGH
  • Patent number: 9556433
    Abstract: Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 31, 2017
    Assignees: Université de Genève, University of Pretoria
    Inventors: Karl-Heinz Krause, Renier Myburgh, Patrick Salmon
  • Publication number: 20160010094
    Abstract: Methods for selecting transgenic cells comprising two or more drug resistance genes with a combination of cytotoxic drugs (e.g., trimetrexate (TMTX) and hydroxyurea (HU)). Such selection can be completed in vitro or in vivo. Transgenic cells and vectors comprising combinations of resistance genes are also provided. Transgenic cells of the embodiments can be used as cell based therapeutics, such as for treatment of HIV infection.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Applicants: UNIVERSITY OF PRETORIA, UNIVERSITE DE GENEVE
    Inventors: Karl-Heinz Krause, David Suter, Patrick Salmon, Renier Myburgh, Michael Pepper
  • Publication number: 20150176006
    Abstract: Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.
    Type: Application
    Filed: September 13, 2013
    Publication date: June 25, 2015
    Applicants: UNIVERSITY OF PRETORIA, UNIVERSITE DE GENEVE
    Inventors: Karl-Heinz Krause, Renier Myburgh, Patrick Salmon